antibody fragment EphB4/Raf inhibitors (Oncalis)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameantibody fragment EphB4/Raf inhibitors (Oncalis)

Drug Alias Nameantibody fragment EphB4/Raf inhibitors (ESBATech)ONC-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionC-Raf kinase inhibitorsEphrin type-B receptor 4 antagonistsSerine/threonine-protein kinase B-raf inhibitors

TargetsC-Raf kinaseEphrin type-B receptor 4Serine/threonine-protein kinase B-raf

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEsbatech Ag

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A